Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
The newly formed company, which began trading on Nasdaq this week, faces intense volatility following the finalized deal and ahead of a planned reverse stock split.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.
The communications technology firm has completed its merger with Core Gaming and will relaunch on October 7th as an artificial intelligence holding company.
The sale of the controlling interest in the insurance platform represents a significant and rapid return on investment for White Mountains.
With a potential market of 128 million in the U.S., analysts see blockbuster potential for the new presbyopia treatment.
A notorious ransomware group claims to have stolen sensitive corporate data, putting Oracle's reputation and customer security under scrutiny.